Program
TAK-360
A development code.
Its studies are mostly in Idiopathic Hypersomnia · Narcolepsy, led by Takeda.
Furthest: phase 3, since Jun 9, 20264 company-led studies, 4 open or runningNext primary completion: Nov 30, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 44 open or running | phase 3since Jun 9, 2026 | Feb 3, 2025 | Nov 30, 2026phase 2 · NCT06952699 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 3, 2025First study: phase 2 study in Idiopathic HypersomniaFirst studyNCT06812078 · 96 planned · United States, France, Hong Kong and more
- Apr 23, 2025Phase 2 study in Narcolepsy Type 2NCT06952699 · 88 planned · United States, China, France and more
- Jun 2, 2026Phase 2 study in NarcolepsyNCT07633301 · 92 planned · United States, Australia, China and more
- Jun 9, 2026Phase 3 study in Idiopathic HypersomniaPhase 3 reachedNCT07646678 · 500 planned · United States, Australia, China and more
Ahead
- Nov 30, 2026Primary completion: phase 2 study in Narcolepsy Type 2NCT06952699
- Nov 30, 2026Primary completion: phase 2 study in Idiopathic HypersomniaNCT06812078
- Nov 28, 2027Primary completion: phase 2 study in NarcolepsyNCT07633301
- Jun 15, 2031Primary completion: phase 3 study in Idiopathic HypersomniaNCT07646678
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07646678Idiopathic Hypersomnia · United States, Australia, China and more | 3 | Recruiting | Jun 15, 2031 | 500 |
| NCT07633301Narcolepsy · United States, Australia, China and more | 2 | Recruiting | Nov 28, 2027 | 92 |
| NCT06952699Narcolepsy Type 2 · United States, China, France and more | 2 | Recruiting | Nov 30, 2026 | 88 |
| NCT06812078Idiopathic Hypersomnia · United States, France, Hong Kong and more | 2 | Recruiting | Nov 30, 2026 | 96 |
How it is read
Names in the registry
- “TAK-360”, 4 entries
Codes read as this program: TAK360.
Conditions, from the studies’ own filings
- Idiopathic Hypersomnia, 2 studies
- Narcolepsy, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.